Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| CisplatinNCT05403723 | University of Maryland, BaltimorePHASE1 | SUSPENDED PI changed institution. Not yet approved at current location. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Etoposide InjectionNCT05403723 | University of Maryland, BaltimorePHASE1 | SUSPENDED PI changed institution. Not yet approved at current location. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Durvalumab 50 MG/1 ML Intravenous SolutionNCT05403723 | University of Maryland, BaltimorePHASE1 | SUSPENDED PI changed institution. Not yet approved at current location. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| AtezolizumabNCT04402788 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRENCT04111172 | Thomas Jefferson UniversityPHASE2 | SUSPENDED Protocol is with FDA review, waiting for funding to be released | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Standard CareNCT03532022 | Neurocrine UK LimitedPHASE3 | WITHDRAWN Protocol re-design required following EU Phase III results | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Chronocort®NCT03532022 | Neurocrine UK LimitedPHASE3 | WITHDRAWN Protocol re-design required following EU Phase III results | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| GARDASIL®9NCT07224477 | Merck Sharp & Dohme LLCPHASE2 | WITHDRAWN Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| V540A-3NCT07224477 | Merck Sharp & Dohme LLCPHASE2 | WITHDRAWN Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| V540A-2NCT07224477 | Merck Sharp & Dohme LLCPHASE2 | WITHDRAWN Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| TalzennaNCT04982848 | PfizerPhase unknown | WITHDRAWN Withdrawal of the marketing authorization for the breast cancer indication of Talzenna® in Korea, not related to safety concerns or any regulatory authority request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Arm 2 cemiplimab and fianlimabNCT07365839 | Virginia Commonwealth UniversityPHASE1 | WITHDRAWN The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Arm 1 cemiplimabNCT07365839 | Virginia Commonwealth UniversityPHASE1 | WITHDRAWN The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| OPC-415NCT04649073 | Otsuka Pharmaceutical Co., Ltd.PHASE1, PHASE2 | TERMINATED This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Pomaglumetad methionilNCT01487083 | Denovo Biopharma LLCPHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| QuetiapineNCT01129674 | Denovo Biopharma LLCPHASE2, PHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| RisperidoneNCT01129674 | Denovo Biopharma LLCPHASE2, PHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| AripiprazoleNCT01129674 | Denovo Biopharma LLCPHASE2, PHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| OlanzapineNCT01129674 | Denovo Biopharma LLCPHASE2, PHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| LY2140023NCT01129674 | Denovo Biopharma LLCPHASE2, PHASE3 | TERMINATED The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| BevacizumabNCT04634604 | Jaeb Center for Health ResearchPHASE3 | TERMINATED Lack of feasibility to recruit. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Saline and SalineNCT04802408 | Milton S. Hershey Medical CenterPHASE2, PHASE3 | TERMINATED technical difficulties in sample analysis | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Shampoo and ListerineNCT04802408 | Milton S. Hershey Medical CenterPHASE2, PHASE3 | TERMINATED technical difficulties in sample analysis | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Saline and ListerineNCT04802408 | Milton S. Hershey Medical CenterPHASE2, PHASE3 | TERMINATED technical difficulties in sample analysis | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Shampoo and salineNCT04802408 | Milton S. Hershey Medical CenterPHASE2, PHASE3 | TERMINATED technical difficulties in sample analysis | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |